Literature DB >> 10646695

Antisense oligodeoxynucleotides targeted to MAG mRNA profoundly alter BP and PLP mRNA expression in differentiating oligodendrocytes: a caution.

I Laszkiewicz1, R C Wiggins, G W Konat.   

Abstract

The applicability of antisense technology to suppress the expression of myelin associated glycoprotein (MAG) in cultured oligodendrocytes was evaluated. Differentiating oligodendrocyte precursor cells obtained by the shake-off method were exposed to nine unmodified antisense oligodeoxynucleotides (ODNs) targeted to the first seven exons of MAG mRNA. After four days, steady-state levels of MAG, proteolipid protein (PLP) and basic protein (BP) mRNAs were determined by Northern blot analysis. Only ODN annealing to 599-618 nt of the MAG mRNA (the junction of exon 5 and 6) resulted in a significant, 75% decrease in the MAG mRNA level. Unexpectedly, six other anti-MAG ODNs which had no significant effect on the MAG message, greatly increased the level of BP mRNA. The highest upregulation of approximately 12 fold was observed with ODN annealing to 139-168 nt (junction of exon 3 and 4). On the other hand, the 997-1016 ODN decreased the levels of BP and PLP messages by 70-80%. The 599-618 ODN also decreased the PLP mRNA by 85%. The results demonstrate that antisense ODNs targeted to one gene may profoundly alter the expression of other genes, and hence, complicate functional analysis of the targeted protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646695     DOI: 10.1023/a:1020666826384

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  23 in total

1.  Structural characterization of myelin-associated glycoprotein gene core promoter.

Authors:  I Laszkiewicz; B Grubinska; R C Wiggins; G W Konat
Journal:  J Neurosci Res       Date:  1997-12-15       Impact factor: 4.164

Review 2.  Progress in antisense oligonucleotide therapeutics.

Authors:  S T Crooke; C F Bennett
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

3.  Selenium is required for normal upregulation of myelin genes in differentiating oligodendrocytes.

Authors:  J Gu; J E Royland; R C Wiggins; G W Konat
Journal:  J Neurosci Res       Date:  1997-03-15       Impact factor: 4.164

4.  Purine nucleosides and nucleotides stimulate proliferation of a wide range of cell types.

Authors:  M P Rathbone; P J Middlemiss; J W Gysbers; S DeForge; P Costello; R F Del Maestro
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

5.  Nucleotide sequences of two mRNAs for rat brain myelin proteolipid protein.

Authors:  R J Milner; C Lai; K A Nave; D Lenoir; J Ogata; J G Sutcliffe
Journal:  Cell       Date:  1985-10       Impact factor: 41.582

6.  The structure of rat 28S ribosomal ribonucleic acid inferred from the sequence of nucleotides in a gene.

Authors:  Y L Chan; J Olvera; I G Wool
Journal:  Nucleic Acids Res       Date:  1983-11-25       Impact factor: 16.971

7.  Differentiation-specific demethylation of myelin associated glycoprotein gene in cultured oligodendrocytes.

Authors:  B Grubinska; I Laszkiewicz; J Royland; R C Wiggins; G W Konat
Journal:  J Neurosci Res       Date:  1994-10-15       Impact factor: 4.164

8.  Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein.

Authors:  M E DeBellard; S Tang; G Mukhopadhyay; Y J Shen; M T Filbin
Journal:  Mol Cell Neurosci       Date:  1996-02       Impact factor: 4.314

9.  Two forms of 1B236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing.

Authors:  C Lai; M A Brow; K A Nave; A B Noronha; R H Quarles; F E Bloom; R J Milner; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration.

Authors:  G Mukhopadhyay; P Doherty; F S Walsh; P R Crocker; M T Filbin
Journal:  Neuron       Date:  1994-09       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.